Personal information

No personal information available

Activities

Collapse all

Works (18)

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study

American Journal of Hematology
2025-03 | Journal article
DOI: 10.1002/ajh.27553
Contributors: Hippolyte Guerineau; Jean‐Michel Cayuela; Stéphanie Dulucq; Violaine Tran Quang; Sihem Tarfi; Guillaume Gricourt; Quentin Barathon; Corine Joy; Orianne Wagner‐Ballon; Stéphane Morisset et al.
Source: check_circle
Crossref

Beta‐thalassaemia intermedia due to a complex alpha‐globin rearrangement and a heterozygous beta thalassaemia mutation

British Journal of Haematology
2024-11 | Journal article
DOI: 10.1111/bjh.19715
Contributors: Victor Marin; Yoann Huguenin; Lucile Bessi; Laurent Weinmann; Vanessa Augis; Arnaud Desclaux; Louis Lebreton; Stephanie Dulucq; Julian Boutin
Source: check_circle
Crossref

Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis

Circulation: Arrhythmia and Electrophysiology
2024-10 | Journal article
DOI: 10.1161/CIRCEP.124.012732
Contributors: Miruna A. Popa; Sandrine Venier; Roberto Menè; Domenico Giovanni Della Rocca; Frédéric Sacher; Nicolas Derval; Mélèze Hocini; Stéphanie Dulucq; Guido Caluori; Stéphane Combes et al.
Source: check_circle
Crossref

BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis

American Journal of Hematology
2024-08 | Journal article
DOI: 10.1002/ajh.27359
Contributors: Camille Kockerols; Peter J. M. Valk; Stéphanie Dulucq; Franck‐Emmanuel Nicolini; François‐Xavier Mahon; Ehab Atallah; Michael J. Mauro; Jerald P. Radich; Simona Bernardi; Domenico Russo et al.
Source: check_circle
Crossref

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Journal of Clinical Oncology
2024-06-01 | Journal article
DOI: 10.1200/JCO.23.01647
Contributors: Francois-Xavier Mahon; Markus Pfirrmann; Stéphanie Dulucq; Andreas Hochhaus; Panayiotis Panayiotidis; Antonio Almeida; Jiri Mayer; Henrik Hjorth-Hansen; Jeroen J.W.M. Janssen; Satu Mustjoki et al.
Source: check_circle
Crossref

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

British Journal of Haematology
2024-04 | Journal article
DOI: 10.1111/bjh.19330
Contributors: Vincent Alcazer; Stéphane Morisset; Delphine Rea; Laurence Legros; Stéphanie Dulucq; Sandrine Hayette; Jean‐Michel Cayuela; Françoise Huguet; François‐Xavier Mahon; Gabriel Etienne et al.
Source: check_circle
Crossref

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

British Journal of Haematology
2023-06 | Journal article
DOI: 10.1111/bjh.18796
Contributors: Stéphanie Dulucq; Françoise Rigal‐Huguet; Franck E. Nicolini; Pascale Cony‐Makhoul; Martine Escoffre‐Barbe; Martine Gardembas; Laurence Legros; Philippe Rousselot; Jixing Liu; Delphine Rea et al.
Source: check_circle
Crossref

Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527778
Contributors: Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille et al.
Source: check_circle
Crossref

Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527778.v1
Contributors: Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille et al.
Source: check_circle
Crossref

Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22471089
Contributors: Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille et al.
Source: check_circle
Crossref

Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22471089.v1
Contributors: Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille et al.
Source: check_circle
Crossref

Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study

British Journal of Haematology
2021-07 | Journal article
DOI: 10.1111/bjh.17521
Contributors: Stuart Scott; Ashley Cartwright; Sebastian Francis; Liam Whitby; A. Pia Sanzone; André Mulder; Sara Galimberti; Stephanie Dulucq; Carole Mauté; Calogero Lauricella et al.
Source: check_circle
Crossref

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients

Cancers
2020-09 | Journal article | Author
DOI: 10.3390/cancers12092521
Contributors: Gabriel Etienne; Stephanie Dulucq; Frederic Bauduer; Didier Adiko; François Lifermann; Corinne Dagada; Caroline Lenoir; Anna Schmitt; Emilie Klein; Samia Madene et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML

Cancer Research
2020-06-01 | Journal article
DOI: 10.1158/0008-5472.CAN-19-2175
Contributors: Tom Hähnel; Christoph Baldow; Joëlle Guilhot; François Guilhot; Susanne Saussele; Satu Mustjoki; Stefanie Jilg; Philipp J. Jost; Stephanie Dulucq; François-Xavier Mahon et al.
Source: check_circle
Crossref

A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study

British Journal of Haematology
2020-05 | Journal article
DOI: 10.1111/bjh.16511
Contributors: Gabriel Etienne; Stéphanie Dulucq; Carole Faberes; Fontanet Bijou; Anna Schmitt; Emilie Klein; Marie‐Pierre Fort; Françoise Durrieu; Emilie Toulza; François‐Xavier Mahon
Source: check_circle
Crossref

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years

British Journal of Haematology
2020-05 | Journal article
DOI: 10.1111/bjh.16408
Contributors: Stéphanie Dulucq; Cyril Astrugue; Gabriel Etienne; François‐Xavier Mahon; Antoine Benard
Source: check_circle
Crossref

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Clinical Cancer Research
2019-11-15 | Journal article
DOI: 10.1158/1078-0432.CCR-18-3373
Contributors: Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille et al.
Source: check_circle
Crossref

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line

Annals of Hematology
2019-05 | Journal article
DOI: 10.1007/s00277-019-03633-x
Contributors: Stephanie Dulucq; Gabriel Etienne; Stephane Morisset; Emilie Klein; Claudine Chollet; Fanny Robbesyn; Beatrice Turcq; Isabelle Tigaud; Sandrine Hayette; Franck E. Nicolini et al.
Source: check_circle
Crossref
How many people are using ORCID?